Close Menu

NEW YORK – Suzhou, China-based Alphamab Oncology today announced plans to partner with Sanofi China to study the investigational agent KN026 with the chemotherapy agent docetaxel.

The drug combination will be evaluated as a treatment for patients with HER2-positive breast cancer. Under the terms of the partnership, Alphamab's wholly owned subsidiary Jiangsu Alphamed and Sanofi China will jointly evaluate the drug combination, and Sanofi will be granted an exclusivity period to negotiate the in-licensing of KN026, contingent on the agent achieving certain clinical milestones.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


NTRK fusions are oncogenic drivers in a variety of tumors.

Sponsored by

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Sponsored by

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.


In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.